Hospitalist perspective on the treatment of skin and soft tissue infections

Mayo Clinic Proceedings

Volumn 89, Issue 10, 2014, Pages 1436-1451

  Amin, Alpesh N ^a   Cerceo, Elizabeth A ^b   Deitelzweig, Steven B ^c   Pile, James C ^d   Rosenberg, David J ^e   Sherman, Bradley M ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Surgery   (United States)

^c OCHSNER CLINIC FOUNDATION   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^f Northwell Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CEFAZOLIN; CEFTAROLINE FOSAMIL; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; DICLOXACILLIN; DOXYCYCLINE; LINEZOLID; MINOCYCLINE; NAFCILLIN; ORITAVANCIN; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TEDIZOLID; TELAVANCIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

AEROMONAS HYDROPHILA; ANEMIA; ANOREXIA; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BETA HEMOLYTIC STREPTOCOCCUS; BLOOD CULTURE; BONE MARROW SUPPRESSION; CHILL; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED INFECTION; COMMUNITY ACQUIRED METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DEBRIDEMENT; DECREASED APPETITE; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ECHOGRAPHY; ENTEROBACTER; ENTEROCOCCUS; EOSINOPHILIA; ERYTHEMA; ESCHERICHIA COLI; FEVER; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INTOLERANCE; GRAM STAINING; HEADACHE; HEALTH CARE MANAGEMENT; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HYPOKALEMIA; HYPOTENSION; INFUSION SITE ERYTHEMA; INFUSION SITE PAIN; INSOMNIA; KLEBSIELLA; LUNG INFILTRATE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICTURITION DISORDER; MYOPATHY; NAUSEA; NEUTROPENIA; OPTIC NEURITIS; PAIN; PATIENT CARE; PATIENT COUNSELING; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; PHLEBITIS; PRURITUS; PSEUDOMONAS AERUGINOSA; PUNCH BIOPSY; RASH; RESPIRATORY FAILURE; REVIEW; RHABDOMYOLYSIS; RIGOR; SKIN AND SOFT TISSUE INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STOMATITIS; STREPTOCOCCUS PYOGENES; TASTE DISORDER; TREATMENT FAILURE; URINARY TRACT INFECTION; VIBRIO VULNIFICUS; VOMITING; WOUND DRESSING; COMMUNITY-ACQUIRED INFECTIONS; HEALTH; MEDICAL STAFF; MORBIDITY; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TRENDS;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; GLOBAL HEALTH; HOSPITALISTS; HUMANS; MORBIDITY; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 84908119888     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2014.04.018     Document Type: Review

References (117)

1. A.L. Hersh, H.F. Chambers, J.H. Maselli, and R. Gonzales National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections Arch Intern Med 168 14 2008 1585 1591
2. D.J. Pallin, D.J. Egan, A.J. Pelletier, J.A. Espinola, D.C. Hooper, and C.A. Camargo Jr. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 51 3 2008 291 298
3. J. Edelsberg, C. Taneja, and M. Zervos Trends in US hospital admissions for skin and soft tissue infections Emerg Infect Dis 15 9 2009 1516 1518
4. H.T. Hatoum, K.S. Akhras, and S.J. Lin The attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort study Diagn Microbiol Infect Dis 64 3 2009 305 310
5. A. Jeng, M. Beheshti, J. Li, and R. Nathan The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation Medicine (Baltimore) 89 4 2010 217 226
6. G.J. Moet, R.N. Jones, D.J. Biedenbach, M.G. Stilwell, and T.R. Fritsche Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004) Diagn Microbiol Infect Dis 57 1 2007 7 13
7. J.J. Engemann, Y. Carmeli, and S.E. Cosgrove Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection Clin Infect Dis 36 5 2003 592 598
8. K.M.F. Itani, S. Merchant, S.-J. Lin, K. Akhras, J.C. Alandete, and H.T. Hatoum Outcomes and management costs in patients hospitalized for skin and skin-structure infections Am J Infect Control 39 1 2011 42 49
9. C. Liu, A. Bayer, and S.E. Cosgrove Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children Clin Infect Dis 52 3 2011 e18 e55
10. Teflaro [prescribing information] 2012 Forest Laboratories Inc New York, NY
11. Tygacil [prescribing information] 2013 Wyeth Pharmaceuticals Inc Philadelphia, PA
12. Vibativ [prescribing information] 2013 Theravance Inc South San Francisco, CA
13. M. Rybak, B. Lomaestro, and J.C. Rotschafer Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 66 1 2009 82 98
14. D.L. Stevens, A.L. Bisno, and H.F. Chambers Practice guidelines for the diagnosis and management of skin and soft-tissue infections Clin Infect Dis 41 10 2005 1373 1406
15. Cleocin HCl [prescribing information] 2013 Pfizer New York, NY
16. Cleocin phosphate [prescribing information] 2013 Pfizer New York, NY
17. D.A. Anaya, and E.P. Dellinger Necrotizing soft-tissue infection: diagnosis and management Clin Infect Dis 44 5 2007 705 710
18. R.M. Wachter, L. Goldman, and H. Hollander Hospital Medicine 2nd ed. 2005 Lippincott Williams & Wilkins Philadelphia, PA
19. B. Perl, N.P. Gottehrer, D. Raveh, Y. Schlesinger, B. Rudensky, and A.M. Yinnon Cost-effectiveness of blood cultures for adult patients with cellulitis Clin Infect Dis 29 6 1999 1483 1488
20. T. Duvanel, R. Auckenthaler, P. Rohner, M. Harms, and J.H. Saurat Quantitative cultures of biopsy specimens from cutaneous cellulitis Arch Intern Med 149 2 1989 293 296
21. S. Chira, and L.G. Miller Staphylococcus aureus is the most common identified cause of cellulitis: a systematic review Epidemiol Infect 138 3 2010 313 317
22. R. Gaspari, M. Dayno, J. Briones, and D. Blehar Comparison of computerized tomography and ultrasound for diagnosing soft tissue abscesses Crit Ultrasound J 4 1 2012 5
23. K. Iverson, D. Haritos, R. Thomas, and N. Kannikeswaran The effect of bedside ultrasound on diagnosis and management of soft tissue infections in a pediatric ED Am J Emerg Med 30 8 2012 1347 1351
24. B.T. Squire, J.C. Fox, and C. Anderson ABSCESS: applied bedside sonography for convenient evaluation of superficial soft tissue infections Acad Emerg Med 12 7 2005 601 606
25. N. Zacharias, G.C. Velmahos, and A. Salama Diagnosis of necrotizing soft tissue infections by computed tomography Arch Surg 145 5 2010 452 455
26. K.T. Kim, Y.J. Kim, and J. Won Lee Can necrotizing infectious fasciitis be differentiated from nonnecrotizing infectious fasciitis with MR imaging? Radiology 259 3 2011 816 824
27. M.R. Schmid, T. Kossmann, and S. Duewell Differentiation of necrotizing fasciitis and cellulitis using MR imaging AJR Am J Roentgenol 170 3 1998 615 620
28. R.N. Jones, R.E. Mendes, and H.S. Sader Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study J Antimicrob Chemother 65 suppl 4 2010 iv17 iv31
29. R.M. Mera, J.A. Suaya, and H. Amrine-Madsen Increasing role of Staphylococcus aureus and community-acquired methicillin-resistant Staphylococcus aureus infections in the United States: a 10-year trend of replacement and expansion Microbiol Drug Resist 17 2 2011 321 328
30. G.T. Ray, J.A. Suaya, and R. Baxter Microbiology of skin and soft tissue infections in the age of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 76 1 2013 24 30
31. B.A. Lipsky, A.R. Berendt, and P.B. Cornia 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections Clin Infect Dis 54 12 2012 132 173
32. L.G. Miller, F. Perdreau-Remington, and G. Rieg Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles N Engl J Med 352 14 2005 1445 1453
33. M.D. Zilberberg, A.F. Shorr, and S.T. Micek Epidemiology and outcomes of hospitalizations with complicated skin and skin-structure infections: implications of healthcare-associated infection risk factors Infect Control Hosp Epidemiol 30 12 2009 1203 1210
34. Centers for Disease Control and Prevention Methicillin-resistant Staphylococcus aureus infections among competitive sports participants - Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003 MMWR Morb Mortal Wkly Rep 52 33 2003 793 795
35. M. Gilbert, J. MacDonald, and D. Gregson Outbreak in Alberta of community-acquired (USA300) methicillin-resistant Staphylococcus aureus in people with a history of drug use, homelessness or incarceration CMAJ 175 2 2006 149 154
36. S.K. Fridkin, J.C. Hageman, M. Morrison Active Bacterial Core Surveillance Program of the Emerging Infections Program Network Methicillin-resistant Staphylococcus aureus disease in three communities N Engl J Med 352 14 2005 1436 1444
37. K.J. Popovich, R.A. Weinstein, and B. Hota Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis 46 6 2008 787 794
38. G. Lina, Y. Piémont, and F. Godail-Gamot Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia Clin Infect Dis 29 5 1999 1128 1132
39. J.T. Weber Community-associated methicillin-resistant Staphylococcus aureus Clin Infect Dis 41 suppl 4 2005 S269 S272
40. M.E. Stryjewski, and H.F. Chambers Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 46 suppl 5 2008 S368 S377
41. B.E. Gonzalez, A.M. Rueda, S.A. Shelburne III, D.M. Musher, R.J. Hamill, and K.G. Hultén Community-associated strains of methicillin-resistant Staphylococcus aureus as the cause of healthcare-associated infection Infect Control Hosp Epidemiol 27 10 2006 1051 1056
42. U. Seybold, E.V. Kourbatova, and J.G. Johnson Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections Clin Infect Dis 42 5 2006 647 656
43. M.D. Zilberberg, P. Chaudhari, and B.H. Nathanson Development and validation of a bedside risk score for MRSA among patients hospitalized with complicated skin and skin structure infections BMC Infect Dis 12 2012 154
44. A.K. Venkatesh, B.P. Geisler, J.J. Gibson Chambers, C.W. Baugh, J.S. Bohan, and J.D. Schuur Use of observation care in US emergency departments, 2001 to 2008 PLoS One 6 9 2011 e24326
45. L.J. Eron, B.A. Lipsky, D.E. Low, D. Nathwani, A.D. Tice, and G.A. Volturo Managing skin and soft tissue infections: expert panel recommendations on key decision points J Antimicrob Chemother 52 suppl 1 2003 i3 i17
46. G. Lindbeck, and R. Powers Outpatient parenteral antibiotic therapy: management of serious infections: part II, amenable infections and models for delivery: cellulitis Hosp Pract (Off Ed) 28 suppl 2 1993 10 14
47. R. Roberts Management of patients with infectious diseases in an emergency department observation unit Emerg Med Clin North Am 19 1 2001 187 207
48. J.W. Schrock, S. Laskey, and R.K. Cydulka Predicting observation unit treatment failures in patients with skin and soft tissue infections Int J Emerg Med 1 2 2008 85 90
49. K.A. Volz, L. Canham, E. Kaplan, L.D. Sanchez, N.I. Shapiro, and S.A. Grossman Identifying patients with cellulitis who are likely to require inpatient admission after a stay in an ED observation unit Am J Emerg Med 31 2 2013 360 364
50. McKesson Corporation InterQual Level of Care Criteria 2013: Acute Care 2013 McKesson Corporation San Francisco, CA ADLT-378
51. Centers for Medicare & Medicaid Services Department of Health and Human Services. Medicare program; hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and Fiscal Year 2014 rates; quality reporting requirements for specific providers; hospital conditions of participation; payment policies related to patient status: final rule Fed Regist 78 160 2013 50495 51040
52. Centers for Medicare and Medicaid Service. Special Open Door Forum: Final Rule CMS 1599-F: Discussion of the Hospital Inpatient Admission Order and Certification; 2 Midnight Benchmark for Inpatient Hospital Admissions. http://www.cms.gov/Outreach-and-Education/Outreach/OpenDoorForums/Downloads/121913SODFFinalRuleCMS1599F.pdf. Accessed December 3, 2013.
53. A.K. May, R.E. Stafford, E.M. Bulger Surgical Infection Society Treatment of complicated skin and soft tissue infections Surg Infect 10 5 2009 467 499
54. A. Berger, G. Oster, J. Edelsberg, X. Huang, and D.J. Weber Initial treatment failure in patients with complicated skin and skin structure infections Surg Infect 14 3 2013 304 312
55. S.S. Richter, K.P. Heilmann, and S.E. Beekmann Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003 Clin Infect Dis 41 5 2005 599 608
56. H.S. Sader, R.K. Flamm, D.J. Farrell, and R.N. Jones Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program Clin Infect Dis 55 suppl 3 2012 S181 S186
57. S.S. Awad, S.I. Elhabash, L. Lee, B. Farrow, and D.H. Berger Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy Am J Surg 194 5 2007 606 610
58. A. Berger, J. Edelsberg, G. Oster, X. Huang, and D.J. Weber Patterns of initial antibiotic therapy for complicated skin and skin structure infections (cSSSI) in US hospitals, 2000-2009 Infect Dis Clin Pract 21 3 2013 159 167
59. N. Markowitz, E.L. Quinn, and L.D. Saravolatz Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection Ann Intern Med 117 5 1992 390 398
60. L.B. Givner Periorbital versus orbital cellulitis Pediatr Infect Dis J 21 12 2002 1157 1158
61. J.J. Ruhe, N. Smith, R.W. Bradsher, and A. Menon Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome Clin Infect Dis 44 6 2007 777 784
62. US Food and Drug Administration Guidance for Industry: Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment October 2013 US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Rockville, MD http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071185.pdf Accessed October 31, 2013.
63. Cubicin [prescribing information] 2012 Cubist Pharmaceuticals Inc Lexington, MA
64. Vancomycin [prescribing information] 2010 Pfizer Labs New York, NY
65. Zyvox [prescribing information] 2013 Pfizer Inc New York, NY
66. L.K. McDougal, G.E. Fosheim, and A. Nicholson Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States Antimicrob Agents Chemother 54 9 2010 3804 3811
67. B.M. Wright, and E.H. Eiland III Retrospective analysis of clinical and cost outcomes associated with methicillin-resistant Staphylococcus aureus complicated skin and skin structure infections treated with daptomycin, vancomycin, or linezolid J Pathog 2011 2011 347969
68. P.S. McKinnon, S.V. Sorensen, L.Z. Liu, and K.M. Itani Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections Ann Pharmacother 40 6 2006 1017 1023
69. S.L. Davis, P.S. McKinnon, and L.M. Hall Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes Pharmacotherapy 27 12 2007 1611 1618
70. I.M. Gould, M.Z. David, and S. Esposito New insights into methicillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance Int J Antimicrob Agents 39 2 2012 96 104
71. I.M. Gould Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 66 suppl 4 2011 iv17 iv21
72. M.E. Stryjewski, D.R. Graham, S.E. Wilson on behalf of the Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms Clin Infect Dis 46 11 2008 1683 1693
73. J.E. Frampton Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia Drugs 73 10 2013 1067 1094
74. S. Deresinski Counterpoint: vancomycin and Staphylococcus aureus - an antibiotic enters obsolescence Clin Infect Dis 44 12 2007 1543 1548
75. S.E. Cosgrove, K.C. Carroll, and T.M. Perl Staphylococcus aureus with reduced susceptibility to vancomycin Clin Infect Dis 39 4 2004 539 545
76. S. Deresinski Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus J Infect Dis 199 5 2009 605 609
77. C. Liu, and H.F. Chambers Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods Antimicrob Agents Chemother 47 10 2003 3040 3045
78. F.C. Tenover, and R.C. Moellering Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 44 9 2007 1208 1215
79. G. Sakoulas, P.A. Moise-Broder, J. Schentag, A. Forrest, R.C. Moellerging Jr., and G.M. Eliopoulos Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia J Clin Microbiol 42 6 2004 2398 2402
80. L.K. Hidayat, D.I. Hsu, R. Quist, K.A. Shriner, and A. Wong-Beringer High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity Arch Intern Med 166 19 2006 2138 2144
81. T.P. Lodise, B. Lomaestro, J. Graves, and G.L. Drusano Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity Antimicrob Agents Chemother 52 4 2008 1330 1336
82. D.L. Stevens, D. Herr, H. Lampiris, J.L. Hunt, D.H. Batts, B. Hafkin and the Linezolid MRSA Study Group Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections Clin Infect Dis 34 11 2002 1481 1490
83. D.L. Stevens, L.G. Smith, J.B. Bruss for the Linezolid Skin and Soft Tissue Infections Study Group Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections Antimicrob Agents Chemother 44 12 2000 3408 3413
84. M. Bounthavong, and D.I. Hsu Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis Curr Med Res Opin 26 2 2010 407 421
85. S.L. Gerson, S.L. Kaplan, and J.B. Bruss Hematologic effects of linezolid: summary of clinical experience Antimicrob Agents Chemother 46 8 2002 2723 2726
86. E.W. Boyer, and M. Shannon The serotonin syndrome N Engl J Med 352 11 2005 1112 1120
87. M. Narita, B.T. Tsuji, and V.L. Yu Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome Pharmacotherapy 27 8 2007 1189 1197
88. R.D. Arbeit, D. Maki, F.P. Tally, E. Campanaro, B.I. Eisenstein and the Daptomycin 98-01 and 99-01 Investigators The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections Clin Infect Dis 38 12 2004 1673 1681
89. L. Cui, E. Tominaga, H.M. Neoh, and K. Hiramatsu Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50 3 2006 1079 1082
90. US Food and Drug Administration. FDA Drug Safety Communication: Eosinophilic Pneumonia Associated With the Use of Cubicin (Daptomycin). August 4, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm220273.htm. Accessed January 14, 2014.
91. E.J. Ellis-Grosse, T. Babinchak, N. Dartois, G. Rose, E. Loh for the Tigecycline 300 and 305 cSSSI Study Groups The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam Clin Infect Dis 41 suppl 5 2005 S341 S353
92. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. September 27, 2013. http://www.fda.gov/Drugs/DrugSafety/ucm369580.htm. Accessed October 11, 2013.
93. K.A. Polyzos, M.N. Mavros, K.Z. Vardakas, M.C. Makris, P.I. Rafailidis, and M.E. Falagas Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis PLoS One 7 8 2012 e41870
94. G.R. Corey, M. Wilcox, and G.H. Talbot Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection Clin Infect Dis 51 6 2010 641 650
95. H.D. Friedland, T. O'Neal, and D. Biek CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections Antimicrob Agents Chemother 56 5 2012 2231 2236
96. M.L. Corrado Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections J Antimicrob Chemother 65 suppl 4 2010 iv67 iv71
97. Cubist Pharmaceuticals. Cubist Announces FDA Acceptance of Tedizolid New Drug Application With Priority Review. http://www.cubist.com/news/118-cubist-announces-fda-acceptance-of-tedizolid-new-drug-application-with-priority-review. Accessed December 30, 2013.
98. P. Prokocimer, C. De Anda, E. Fang, P. Mehra, and A. Das Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial JAMA 309 6 2013 559 569
99. E. Seltzer, M.B. Dorr, B.P. Goldstein, M. Perry, J.A. Dowell, T. Henkel Dalbavancin Skin and Soft-Tissue Infection Study Group Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections Clin Infect Dis 37 10 2003 1298 1303
100. Durata Therapeutics Clinical trials 2013 http://www.duratatherapeutics.com/product-pipeline/dalbavancin/clinical-trials Accessed December 23, 2013
101. The Medicines Company. The Medicines Company announces positive results for SOLO II trial of oritavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSI) [news release]. http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol-newsArticle&ID=1834647&highlight=. Accessed December 23, 2013.
102. P.S. McKinnon, A.J. Boening, and A.N. Amin Optimizing delivery of care for patients with MRSA infection: focus on transitions of care Hosp Pract 39 2 2011 18 31
103. J.A. Paladino, and D. Poretz Outpatient parenteral antimicrobial therapy today Clin Infect Dis 51 suppl 2 2010 S198 S208
104. H.H. Nguyen Hospitalist to home: outpatient parenteral antimicrobial therapy at an academic center Clin Infect Dis 51 suppl 2 2010 S220 S223
105. G.J. Moran, F.M. Abrahamian, F. Lovecchio, and D.A. Talan Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines J Emerg Med 44 6 2013 e397 e412
106. Srinivasan A. CDC expert commentary: three steps to antibiotic stewardship. November 15, 2010. http://www.medscape.com/viewarticle/731784. Accessed March 4, 2014.
107. M. Desai, B.D. Franklin, and A.H. Holmes A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay BMC Infect Dis 6 2006 94
108. S. Parodi, D.C. Rhew, and M.B. Goetz Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin-resistant staphylococcal species infections J Managed Care Pharm 9 4 2003 317 326
109. L.J. Eron, and S. Passos Early discharge of infected patients through appropriate antibiotic use Arch Intern Med 161 1 2001 61 65
110. A.J. Forster, H.D. Clark, and A. Menard Adverse events among medical patients after discharge from hospital CMAJ 170 3 2004 345 349
111. S.Z. Pantilat, P.K. Lindenauer, P.P. Katz, and R.M. Wachter Primary care physician attitudes regarding communication with hospitalists Am J Med 111 9B 2001 15S 20S
112. S. Kripalani, A.T. Jackson, J.L. Schnipper, and E.A. Coleman Promoting effective transitions of care at hospital discharge: a review of key issues for hospitalists J Hosp Med 2 5 2007 314 323
113. J. Donzé, D. Aujesky, D. Williams, and J.L. Schnipper Potentially avoidable 30-day hospital readmissions in medical patients: derivation and validation of a prediction model JAMA Intern Med 173 8 2013 632 638
114. C. Van Walraven, M. Mamdani, J. Fang, and P.C. Austin Continuity of care and patient outcomes after hospital discharge J Gen Intern Med 19 6 2004 624 631
115. E.A. Coleman, C. Parry, S. Chalmers, and S.J. Min The care transitions intervention: results of a randomized controlled trial Arch Intern Med 166 17 2006 1822 1828
116. B.W. Jack, V.K. Chetty, and D. Anthony A reengineered hospital discharge program to decrease rehospitalization: a randomized trial Ann Intern Med 150 3 2009 178 187
117. M.D. Naylor, D. Brooten, and R. Campbell Comprehensive discharge planning and home follow-up of hospitalized elders: a randomized clinical trial JAMA 281 7 1999 613 620